Rubedo Raises $40M Series A to Combat Age-Related Diseases

The life sciences company plans to advance its lead therapeutic candidate into phase 1 studies this year.

Published on Apr. 22, 2024
Rubedo Raises $40M Series A to Combat Age-Related Diseases
Photo: Rubedo

Rubedo Life Sciences, a biopharmaceutical company focused on developing therapies for age-related diseases, has closed a $40 million Series A financing round. The funding was led by Khosla Ventures and Ahren Innovation Capital.

Rubedo’s approach targets senescent cells which can accumulate over time and cause chronic inflammation, leading to fibrosis and tissue degeneration. The company’s drug discovery platform, Alembic, identifies pathologic cells like these to develop targeted therapeutics that can prevent or reverse the resulting age-related diseases.

The company plans to use the money to advance its lead candidate into phase 1 studies for chronic atopic dermatitis and chronic psoriasis. Rubedo is also developing therapies for pulmonary diseases such as idiopathic pulmonary fibrosis.

This article was written by Writer, a generative AI tool, using information from press releases and company blogs provided by our staff. All content was reviewed by a Built In editor and went through a fact-checking process to ensure accuracy. Errors can be reported to our team at [email protected].

Hiring Now
Cloud • Information Technology • Machine Learning • Software • Automation